Retatrutide, an experimental weight loss drug, is being sold online and prescribed by some providers, raising concerns about safety risks. The drug's availability on the gray market, where it is often sold as a peptide, has blurred the lines between drugs and supplements, potentially posing health risks to users. The extent of its use and the severity of associated risks are not fully clear, with reports of both excessive weight loss and unregulated sales from foreign sources.